Lincoln Pharmaceuticals Limited (BOM:531633)
India · Delayed Price · Currency is INR 461.50
-4.15 (-0.89%)
At close: Jan 20, 2026
Lincoln Pharmaceuticals Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
Net Income | 800.04 | 823.46 | 933.05 | 728.99 | 693.55 | 622.5 | Upgrade |
Depreciation & Amortization | 134.45 | 127.98 | 105.19 | 90.55 | 79.53 | 74.22 | Upgrade |
Other Amortization | 1.01 | 1.01 | 1.06 | 1.11 | 1.35 | 1.38 | Upgrade |
Loss (Gain) From Sale of Assets | 0.46 | 1.4 | 2.76 | -0.76 | 1.3 | 0.53 | Upgrade |
Loss (Gain) From Sale of Investments | -42.26 | -61.2 | -227.85 | -51.35 | -36.1 | -24.5 | Upgrade |
Provision & Write-off of Bad Debts | -6.28 | 1.49 | 6.5 | -1.78 | 5.27 | 0.91 | Upgrade |
Other Operating Activities | -20.05 | -55.69 | -27.36 | -60.42 | -7.61 | 15.62 | Upgrade |
Change in Accounts Receivable | 167.05 | -47.79 | -260.86 | -202.12 | -31.19 | -100.83 | Upgrade |
Change in Inventory | 39.49 | -15.09 | -71.4 | 27.14 | -261.29 | 7.83 | Upgrade |
Change in Accounts Payable | -66.07 | 125.08 | 215.73 | -205.14 | 145.93 | 55.5 | Upgrade |
Change in Other Net Operating Assets | -3.28 | 29.5 | -44.64 | 66.39 | 170.6 | 39.54 | Upgrade |
Operating Cash Flow | 1,005 | 930.16 | 632.17 | 392.62 | 761.32 | 692.7 | Upgrade |
Operating Cash Flow Growth | 55.31% | 47.14% | 61.01% | -48.43% | 9.91% | -8.15% | Upgrade |
Capital Expenditures | -219.13 | -190.29 | -394.76 | -142.59 | -455.25 | -87.5 | Upgrade |
Sale of Property, Plant & Equipment | 14.46 | 1.22 | 0.9 | 7.06 | 0.79 | 0.65 | Upgrade |
Divestitures | - | - | - | - | - | 0.5 | Upgrade |
Sale (Purchase) of Intangibles | -2.71 | -2.15 | -1.37 | -0.23 | - | - | Upgrade |
Investment in Securities | -476.37 | -286.83 | -248.05 | 106.14 | -125.3 | -439.99 | Upgrade |
Other Investing Activities | 152.94 | 25.38 | 305.48 | -140.95 | -81.26 | 16.15 | Upgrade |
Investing Cash Flow | -840.55 | -789.47 | -573.41 | -366.43 | -780.8 | -642.27 | Upgrade |
Short-Term Debt Issued | - | 684.2 | 200 | 193.57 | 20 | - | Upgrade |
Total Debt Issued | 232.67 | 684.2 | 200 | 193.57 | 20 | - | Upgrade |
Short-Term Debt Repaid | - | -694.17 | -209.02 | -195.02 | - | -38.33 | Upgrade |
Long-Term Debt Repaid | - | - | - | - | -5.2 | -7.21 | Upgrade |
Total Debt Repaid | -245.17 | -694.17 | -209.02 | -195.02 | -5.2 | -45.54 | Upgrade |
Net Debt Issued (Repaid) | -12.5 | -9.97 | -9.02 | -1.44 | 14.8 | -45.54 | Upgrade |
Common Dividends Paid | -35.87 | -36.05 | -30.05 | -30.05 | -30 | - | Upgrade |
Other Financing Activities | -14.21 | -17.99 | -12.74 | -13.52 | -10.36 | -11.91 | Upgrade |
Financing Cash Flow | -62.57 | -64.02 | -51.8 | -45.01 | -25.56 | -57.45 | Upgrade |
Net Cash Flow | 101.44 | 76.67 | 6.95 | -18.82 | -45.04 | -7.03 | Upgrade |
Free Cash Flow | 785.44 | 739.86 | 237.41 | 250.03 | 306.07 | 605.19 | Upgrade |
Free Cash Flow Growth | 208.38% | 211.64% | -5.05% | -18.31% | -49.43% | -10.64% | Upgrade |
Free Cash Flow Margin | 12.43% | 11.87% | 4.09% | 4.90% | 6.48% | 14.27% | Upgrade |
Free Cash Flow Per Share | 39.21 | 36.94 | 11.85 | 12.48 | 15.28 | 30.21 | Upgrade |
Cash Interest Paid | 14.21 | 17.99 | 12.74 | 13.52 | 10.36 | 11.91 | Upgrade |
Cash Income Tax Paid | 253.33 | 263.07 | 261.51 | 296.1 | 236.96 | 194.91 | Upgrade |
Levered Free Cash Flow | 541.12 | 452.3 | 213.14 | 44.59 | 62.93 | 493.48 | Upgrade |
Unlevered Free Cash Flow | 545.17 | 458.52 | 219.05 | 54.82 | 68.68 | 500.99 | Upgrade |
Change in Working Capital | 137.2 | 91.71 | -161.17 | -313.74 | 24.05 | 2.04 | Upgrade |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.